CLIMB BIO INC (CLYM:NASDAQ)
$10.44 -0.76 (-6.7857%)
Analysed CLIMB BIO INC (CLYM:NASDAQ) News Sources
Climb Bio (CLYM) Receives FDA Fast Track Designation for Budoprutug in Rare Kidney Disease
29-04-2026
yahoo.com
Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026
01-05-2026
yahoo.com
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
05-05-2026
yahoo.com
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing
05-05-2026
yahoo.com
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE
05-05-2026
marketbeat.com
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
07-05-2026
yahoo.com
Climb Bio to Present at Upcoming Investor Conferences
12-05-2026
yahoo.com
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
14-05-2026
yahoo.com
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
21-05-2026
marketbeat.com
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
26-05-2026
yahoo.com
What is the current price of CLIMB BIO INC (CLYM:NASDAQ)?
The current price of CLIMB BIO INC (CLYM:NASDAQ) is $10.44.
CLIMB BIO INC (CLYM:NASDAQ) absolute price change since previous trading day?
The absolute price change of CLIMB BIO INC (CLYM:NASDAQ) since the previous trading day is $-0.76.
CLIMB BIO INC (CLYM:NASDAQ) percentage price change since previous trading day?
The percentage price change of CLIMB BIO INC (CLYM:NASDAQ) since the previous trading day is -6.7857%.
What is the most recent average sentiment score for CLIMB BIO INC (CLYM:NASDAQ)?
The most recent average sentiment score for CLIMB BIO INC (CLYM:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for CLIMB BIO INC (CLYM:NASDAQ)?
The most recent sentiment for CLIMB BIO INC (CLYM:NASDAQ) is .
SEC-8K** Filing Available For CLIMB BIO INC (CLYM:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.